Breast cancer patients have increased risk of developing mTOR inhibitor‐associated stomatitis

Abstract

A total of 115 patients who used everolimus were evaluated. The mean age was 57 (±13.3) years old, and 87 patients were women (75.6%). mTOR inhibitor-associated stomatitis (mIAS) was observed in 36 patients (31.3%). The lesions ranged from 0.5 cm to 1.5 cm, and the tongue was the main site affected. In addition, 21 patients (58.3%) required a dose reduction of everolimus due to mIAS. Patients who had breast cancer presented 2.29-fold higher risk for developing mIAS when compared to patients with kidney or neuroendocrine tumors. This study emphasizes the high prevalence of mIAS in patients using everolimus, in particular, in patients with breast cancer.

Synthesis and characterization of Al(III) complex with paracetamol

“…15 In some cases, oral pain does not always match with oral erythema or ulceration presentation. 16 If the suspected mIAS injury or lesions strongly similar to the aphthous ulcers and on mobile mucosa (Figure 1A-C), further diagnostic aids may not be essential after symptom evaluation and examination of clinical characteristics. 17 When the clinician is uncertain about the diagnosis, the role of the culture in these lesions is debated, given the challenge of producing cultures in a microorganism-rich setting.…”

“…Until beginning and throughout treatment, oncology nurses should inform patients on the importance of maintaining good oral health and timely oral pain reporting to an HCS or caregiver and understanding the medical characteristics of mIAS. 16 Pharmacists should address proper medication management, potential drug reactions, and adverse effect monitoring. 26 In terms of reducing morbidity, self-care for patients should not be overlooked, particularly when patients receive educational tools and oral HCS aid.…”